Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes

Endocrine Reviews

Volumn 32, Issue 4, 2011, Pages 515-531

  Abdul Ghani, Muhammad A ^a   Norton, Luke ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTISENSE OLIGONUCLEOTIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PROTEIN INHIBITOR; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL (TOPIC); DISEASE COURSE; DIURESIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION RISK; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLYCOSURIA, RENAL; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 80052362968     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2010-0029     Document Type: Review

References (98)

1. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA 1989 The economic costs of non-insulin-dependent diabetes mellitus. JAMA 262:2708-2713.
2. King H, Aubert RE, Herman WH 1998 Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431.
3. Rathmann W, Giani G 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:2568-2569.
4. Schalkwijk CG, Stehouwer CDA 2005 Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143-159.
5. He Z, King GL 2004 Microvascular complications of diabetes. Endocrinol Metab Clin North Am 33:215-238, xi-xii.
6. Kahn SE, Hull RL, Utzschneider KM 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846.
7. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR 2000 The prevalence of multiple diabetes-related complications. Diabet Med 17:146-151.
8. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986.
9. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
10. DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269.
11. Defronzo RA 2009 Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
12. Rossetti L, Giaccari A, DeFronzo RA 1990 Glucose toxicity. Diabetes Care 13:610-630.
13. Rossetti L, Giaccari A, DeFronzo RA 2007 Standards of medical care in diabetes-2007. Diabetes Care 30(Suppl 1):S4-S41.
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B 2008 Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51: 8-11.
15. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK 2007 Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 147:417-422.
16. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS 2009 Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15:540-559.
17. Brown GK 2000 Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 23: 237-246.
18. Wood IS, Trayhurn P 2003 Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89:3-9.
19. Wright EM, Hirayama BA, Loo DF 2007 Active sugar transport in health and disease. J Intern Med 261:32-43.
20. Wright EM, Loo DD, Hirayama BA, Turk E 2004 Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda) 19:370-376.
21. Turk E, Martín MG, Wright EM 1994 Structure of the human Na+/glucose cotransporter gene SGLT1. J Biol Chem 269:15204-15209.
22. Valtin H 1983 Renal function: mechanisms preserving fluid and solute balance in health. Boston: Little, Brown and Company.
23. Turk E, Klisak I, Bacallao R, Sparkes RS, Wright EM 1993 Assignment of the human Na+/glucose cotransporter gene SGLT1 to chromosome 22q13.1. Genomics 17:752-754.
24. Wright EM, Turk E 2004 The sodium/glucose cotransport family SLC5. Pflugers Arch 447:510-518.
25. Hirayama BA, Lostao MP, Panayotova-Heiermann M, Loo DD, Turk E, Wright EM 1996 Kinetic and specificity differences between rat, human, and rabbit Na+-glucose cotransporters (SGLT-1). Am J Physiol 270:G919-G926.
26. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA 1992 Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263:F459-F465.
27. Kanai Y, Lee WS, You G, Brown D, Hediger MA1994 The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404.
28. Kong CT, Yet SF, Lever JE 1993 Cloning and expression of a mammalian Na+/amino acid cotransporter with sequence similarity to Na+/glucose cotransporters. J Biol Chem 268:1509-1512.
29. Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al 1999 The DNA sequence of human chromosome Nature 402:489-495.
30. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, Volk C, Wright EM, Koepsell H 2003 A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA 100:11753-11758.
31. Freeman SL, Bohan D, Darcel N, Raybould HE 2006 Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose cotransporter. Am J Physiol Gastrointest Liver Physiol 291:G439-G445.
32. Elsas LJ, Rosenberg LE 1969 Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest 48:1845-1854.
33. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D 2003 Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882.
34. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T 2011 SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104-112.
35. Dominguez JH, Camp K, Maianu L, Feister H, GarveyWT 1994 Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 266: F283-F290.
36. Dominguez JH, Song B, Maianu L, Garvey WT, Qulali M 1994 Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol 5(5 Suppl 1):S29-S36.
37. Noonan WT, Shapiro VM, Banks RO 2001 Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci 68:2967-2977.
38. Freitas HS, Anhê GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF 2008 Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology 149:717-724.
39. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J 2005 Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-3434.
40. Kamran M, Peterson RG, Dominguez JH 1997 Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8:943-948.
41. Farber SJ, Berger EY, Earle DP 1951 Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125-129.
42. Mogensen CE 1971 Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 28: 183-193.
43. Gribble FM, Williams L, Simpson AK, Reimann F 2003 A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147-1154.
44. Petersen C 1835 Analyse des Phloridzins. Annales Academie Science Francaise 15:178.
45. Von Mering J 1886 Ueber kunstlichen diabetes. Centralbl Med Wiss 22:531.
46. Alvarado F, Crane RK 1962 Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta 56:170-172.
47. Vick H, Diedrich DF, Baumann K 1973 Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol 224:552-557.
48. Chasis H, Jolliffe N, Smith HW 1933 The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 12:1083-1090.
49. Kolodny EH, Kline R, Altszuler N 1962 Effect of phlorizin on hepatic glucose output. Am J Physiol 202:149-154.
50. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L 1991 Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561-570.
51. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA 1987 Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044.
52. Rossetti L, Smith D, Shulman GI, Papachristou D, De-Fronzo RA 1987 Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515.
53. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J 2005 Phlorizin: a review. Diabetes Metab Res Rev 21:31-38.
54. Wüthrich M, Sterchi EE 1997 Human lactase-phlorizin hydrolase expressed in COS-1 cells is proteolytically processed by the lysosomal pathway. FEBS Lett 405:321-327.
55. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H 1999 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800.
56. Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T 2000 Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 391:183-192.
57. Ueta K, Yoneda H, OkuA, Nishiyama S, Saito A, Arakawa K 2006 Reduction of renal transport maximum for glucose by inhibition of Na(+)-glucose cotransporter suppresses blood glucose elevation in dogs. Biol Pharm Bull 29:114-118.
58. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M 2007 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320:323-330.
59. Pajor AM, Randolph KM, Kerner SA, Smith CD 2008 Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters. J Pharmacol Exp Ther 324: 985-991.
60. Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJ 2010 Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 50:623-635.
61. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN 2008 Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149.
62. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM 2008 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729.
63. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W 2010 Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Diabetes 59(Suppl 1):A21.
64. Polidori D, Zhao Y, Sha S, Canovatchel W 2010 Canagliflozin treatment improves β-cell function in subjects with type 2 diabetes. Diabetes 59(Suppl 1):A176.
65. Schwartz S, Morrow L, Hompesch M, Devinent D, Skee D, Vandebosch A, Murphy J, MP 2010 Canagliflozine improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin. Diabetes 59(Suppl 1):A154.
66. Koiwai K, Seman L, Yamamura N, Macha S, Taniguchi A, Negishi T, Sesoko S, Dugi KA 2010 Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT2), in Japanese healthy volunteers. Diabetes 59(Suppl 1):A571.
67. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S 2010 ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus. Diabetes 59(Suppl 1): A21.
68. Freiman J, Ruff DA, Frazier KS, Combs K, Turnage A, Shadoan M, Powell D, Zambrowicz B, Brown P 2010 LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvements in glycemic control over 28 days in patients with type 2 diabetes (T2DM). Diabetes 59(Suppl 1):A511.
69. Bickel M, Brummerhop H, Frick W, Glombik H, Herling AW, Heuer HO, Plettenburg O, Theis S, Werner U, Kramer W 2008 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 58:574-580.
70. Bhanot S, Murray SF, Booten SL, Chakravarty K, Zanardi T, Henry S, Watts LM, Wancewicz EV, Siwkows A 2009 ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. Diabetes 58 (Suppl 1):A328.
71. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K 2005 Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sci 76:2655-2668.
72. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhäusl W, Shulman GI 2000 Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707.
73. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L 1998 Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 102:744-753.
74. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, DeFronzo RA 1993 Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91:484-494.
75. Oku A, Ueta K, Arakawa K, Kano-Ishihara T, Matsumoto T, Adachi T, Yasuda K, Tsuda K, Ikezawa K, SaitoA 2000 Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats. Jpn J Pharmacol 84:351-354.
76. Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y 2004 Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem 11:2717-2724.
77. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA 2006 Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430-1435.
78. Leahy JL, Bonner-Weir S, Weir GC 1988 Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81:1407-1414.
79. Olson LK, Redmon JB, Towle HC, Robertson RP 1993 Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest 92:514-519.
80. Toschi E, Camastra S, Sironi AM, Masoni A, Gastaldelli A, Mari A, Ferrannini E, Natali A 2002 Effect of acute hyperglycemia on insulin secretion in humans. Diabetes 51(Suppl 1):130-133.
81. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG 1985 The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234.
82. Nunoi K, Yasuda K, Adachi T, Okamoto Y, Shihara N, Uno M, Tamon A, Suzuki N, Oku A, Tsuda K 2002 Ben-eficial effect of T-1095, a selective inhibitor of renal Na -glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 29:386-390.
83. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M 2009 Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85:513-519.
84. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG 2010 In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 38:405-414.
85. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF 2010 Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224.
86. List JF, Woo V, Morales E, Tang W, Fiedorek FT 2009 Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650-657.
87. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233.
88. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT 2009 A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:1656-1662.
89. Nauck M, Del Prato, S, Rohwedder, K, Elze, M, Parikh, S 2010 Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial. Diabetologia 53(Suppl 1):S1-S556.
90. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M 2010 Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12:510-516.
91. Hussey E, Clark R, Amin M, Kipnes M, Semmes R, O'driscoll E, Leong J, Murphy S, Dobbins R, Nunez D 2007 Early clinical studies to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes 56(Suppl 1):A189.
92. Hussey E, Dobbins R, Stolz R, Stockman N, Semmes R, Murray S, Nunez D 2007 A double-blind randomized repeat dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy overweight and obese subjects. Diabetes 56(Suppl 1):A491.
93. Bank N, Aynedjian HS 1990 Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J Clin Invest 86:309-316.
94. Thomson SC, Vallon V, Blantz RC 2004 Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286:F8-F15.
95. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H 1999 Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569-2576.
96. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD 1996 Development and progression of renal disease in Pima Indians with noninsulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335:1636-1642.
97. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA 1991 Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324:1626-1632.
98. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A 2001 Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578-586.